Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie recently completed a clinical study titled ‘A ...
Chewable tablets are a versatile dosage form offering several advantages including oral drug delivery without the need for water, ease of swallowing, the stability advantages of solid dosage forms, ...
ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults Oral ANAVEX®3-71 tablet exhibits superior pharmacokinetics compared to the ...
A case study reviews the reformulation and scale up of high drug load prototype using wet granulation process for a model formulation. v_kurashev/shutterstock.com The reformulation of a 100-mg tablet ...
Positive Results from Clinical Pharmacokinetic Study for the Eosinophilic Esophagitis Specific Formulation with the Drug Candidate AQ280Aqilion today announces positive results from the ARIA-2 ...
The tablet formulation of Brukinsa is supplied as a 160mg dose, allowing patients the convenience of taking only 2 tablets daily. The Food and Drug Administration (FDA) has approved a new tablet ...
With Gift Aid, your generous donation of £10 would be worth £12.50 at no extra cost to you. Yes, I want to Gift Aid any donations made to NAM now, in the future and in the past four years I am a UK ...
The Food and Drug Administration initially approved the chewable tablet formulation in January 2017. Vyvanse (lisdexamfetamine dimesylate; Shire) is now available as chewable tablets for the treatment ...
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback